Core Points - The Gross Law Firm has issued a notice to shareholders of Lantheus Holdings, Inc. regarding a class action lawsuit related to alleged false statements and omissions concerning the company's revenue outlook and market dynamics [1][2] - The class period for the lawsuit is from February 26, 2025, to August 5, 2025, during which shareholders are encouraged to register for potential recovery [2] - Allegations include that Lantheus misrepresented its understanding of the competitive landscape and pricing dynamics for its product Pylarify, leading to inflated stock prices [1] Company Summary - Lantheus Holdings, Inc. is facing allegations of misleading investors about its sales growth potential and market conditions for Pylarify, which may have resulted in artificial inflation of its stock price [1] - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to the alleged deceitful practices of Lantheus [3] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period should register by November 10, 2025, to be included in the case and receive updates [2] - There is no cost or obligation for shareholders to participate in the class action lawsuit [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to contact the firm [6].

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). Accessibility StatementSkip Navigation CONTACT US HERE: Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/lantheus-holdings-inc-loss-submission-f ...

Core Viewpoint - Fluor Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 18, 2025, and July 31, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Fluor Corporation concealed rising costs associated with infrastructure projects, including Gordie Howe, I-635/LBJ, and I-35, due to subcontractor design errors, price increases, and scheduling delays [2]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, significantly affected the Company's business and financial results [2]. - The financial guidance provided by Fluor for FY 2025 is claimed to be unreliable and overstated regarding the effectiveness of its risk mitigation strategy and the impact of economic uncertainty [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating that there was insufficient information about its chemistry, manufacturing, and controls [2]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Semler Scientific, Inc. for alleged securities fraud affecting investors between March 10, 2021, and April 15, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the U.S. Department of Justice regarding violations of the False Claims Act, while discussing potential violations in hypothetical terms [3]. - The complaint alleges that the public statements made by the defendants were materially false and misleading throughout the relevant period [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against RCI Hospitality Holdings, Inc. alleging securities fraud affecting investors between December 15, 2021, and September 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants engaged in tax fraud and bribery to conceal this fraud, leading to an understatement of the legal risks faced by the company [3]. - It is alleged that the defendants' statements regarding the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 20, 2025, to request to be appointed as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for Cytokinetics investors affected by alleged securities fraud between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made materially false statements regarding the expected approval timeline for the NDA for aficamten, claiming approval from the FDA in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - The complaint highlights that the company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA about safety monitoring but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Cytokinetics during the relevant timeframe have until November 17, 2025, to request the Court to appoint them as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fly-E Group, Inc. regarding a class action lawsuit due to misleading statements about the safety of its lithium batteries, which negatively impacted the company's E-vehicle sales and revenue projections [1]. Summary by Sections Allegations - The complaint alleges that Fly-E Group provided overly positive statements while concealing material adverse facts about the safety of its lithium batteries, leading to a significant decline in E-vehicle sales revenue [1]. - On August 14, 2025, Fly-E reported a 32% decrease in net revenues, primarily due to a drop in total units sold, which was attributed to recent lithium-battery accidents involving E-Bikes and E-Scooters [1]. - Following this revelation, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share, marking an approximate 87% decline in just one day [1]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by November 10, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Cytokinetics, Incorporated, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to significant losses for shareholders [1]. Group 1: Allegations and Timeline - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which shareholders are encouraged to contact the firm for potential lead plaintiff appointment [1]. - The complaint states that Cytokinetics misrepresented the expected FDA approval timeline for aficamten, claiming it would occur in the second half of 2025 based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [1]. - On May 6, 2025, it was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, which misled investors about the regulatory timeline [1]. Group 2: Impact on Shareholders - As a result of the misleading statements, shareholders purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth about the NDA submission was disclosed [1]. - Shareholders are advised to register for the class action by November 17, 2025, to participate in the case without any cost or obligation [2]. Group 3: Legal Representation - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].